ANKRD1 Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ANKRD1 gene in the HeLa background. This polyclonal format provides a heterogeneous pool of cells with targeted gene disruption, enabling loss-of-function studies without clonal isolation. The product is generated using a ribonucleoprotein-based editing strategy and is intended for immediate use in transient or stable functional assays. Researchers can employ this model to interrogate ANKRD1-dependent phenotypes in a well-characterized human cancer cell line, with the polyclonal nature offering a broader representation of edited genotypes compared to single-cell clones.
HeLa cells are a human cervical adenocarcinoma line that is HPV18-positive and serves as a widely adopted immortalized cancer model system. Their robust proliferation, ease of transfection, and extensive characterization make them a preferred host for CRISPR-based knockout experiments. HeLa cells retain active mechanotransduction and TGF-beta signaling pathways, providing a context in which ANKRD1??s roles in stress-responsive transcription can be dissected. The cell line??s tumor origin also facilitates exploration of ANKRD1 function in oncogenic signaling and cellular adaptation to microenvironmental cues.
ANKRD1 (ankyrin repeat domain 1) encodes a transcriptional co-regulator that operates at the intersection of mechanical stress and growth factor signaling. It is activated by mechanical stretch and TGF-beta, functioning downstream of p53 and MEF2, and interacts directly with transcription factors YAP1, GATA4, Nkx2-5, and p53. Through these interactions, ANKRD1 modulates the expression of target genes such as alpha-actin, myosin heavy chain, and fibrotic gene programs, often in concert with SMAD2/3 and TEAD transcriptional complexes. Additionally, ANKRD1 associates with the giant sarcomeric protein titin, linking mechanical strain to nuclear transcriptional responses. Depletion of ANKRD1 disrupts these multiprotein complexes, making the knockout model a powerful tool for studying mechanotransduction and TGF-beta?Cinduced gene regulation.
In the HeLa host context, ANKRD1 knockout allows researchers to examine how loss of this cofactor alters YAP1/TEAD-mediated transcriptional output, TGF-beta?Cdriven SMAD2/3 activation, and the expression of cytoskeletal and fibrotic effectors. HeLa cells exhibit baseline activation of Hippo pathway components, and ANKRD1 disruption can modify YAP/TAZ nuclear localization and target gene induction in response to substrate stiffness or ligand stimulation. The model is thus relevant for probing the molecular basis of dilated and hypertrophic cardiomyopathies, as well as congenital heart defects, in a non-cardiac cellular environment where core mechanosensory modules remain intact. This approach avoids confounding differentiation cues present in primary myocytes while preserving key signaling nodes.
Typical applications include western blotting to assess changes in YAP1, phospho-SMAD2, or GATA4 levels; RT-qPCR profiling of downstream targets such as CTGF, CYR61, and fibronectin; immunofluorescence analysis of YAP/TAZ subcellular localization; luciferase reporter assays for ANKRD1-responsive promoters; and migration assays to evaluate cellular response to mechanical cues. These applications support mechanistic studies in mechanobiology, TGF-beta signal transduction, and Hippo-YAP axis investigation, facilitating drug screening and target validation. For further information, please contact Ascent Research.
